2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
This guideline cites 6 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2019
- Source
- Arnett DK, Blumenthal RS, et al. Circulation. 2019;140(11):e596–e646.doi 10.1161/CIR.0000000000000678
The 2019 guideline is the American counterpart to the ESC 2021 prevention document, and the two differ mainly in how risk is quantified and how aggressively aspirin is abandoned. Risk here rests on the Pooled Cohort Equations plus 'risk-enhancing factors' and, in the borderline-to-intermediate range, a coronary artery calcium score — where the ESC uses SCORE2/SCORE2-OP and no routine calcium scoring. Aspirin for primary prevention is downgraded to a narrow, selectively applied option (Class IIb, and Class III: Harm above 70 years) on the strength of ASCEND, ASPREE and ARRIVE. Blood pressure is treated to <130/80 mmHg and statins are prescribed by risk category rather than to an LDL-C target. Because the document closed in 2019, later prevention landmarks appear in a separate section below.
Lipid lowering1
- 2008JUPITERCardiology · Lipids · StatinsIn 17,802 adults with LDL < 130 mg/dL and hsCRP ≥ 2 mg/L, rosuvastatin reduced major vascular events versus placebo.HR 0.56Read →
Blood-pressure lowering1
- 2015SPRINT CoreCardiology · HTN · BP targetIn 9,361 high-risk non-diabetic hypertensive adults, intensive BP control to SBP < 120 mm Hg reduced CV events and all-cause mortality compared with standard control to SBP < 140 mm Hg.HR 0.75Read →
Diabetes & cardiometabolic risk4
- 2019DECLARE-TIMI 58Cardiology · Cardiometabolic · SGLT2 inhibitorsIn 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.83Read →
- 2016LEADERCardiology · Cardiometabolic · GLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2016SUSTAIN-6Endocrinology · GLP-1 RA · CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.HR 0.74Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
Published since the guideline4
- 2024FLOW CoreNephrology · CKD · GLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →
- 2023CLEAR OutcomesCardiology · Lipids · Non-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2023SELECT CoreCardiology · Cardiometabolic · GLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →
- 2021STEP 1Endocrinology · Obesity · Semaglutide for obesityIn 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.-14.9% vs -2.4%Read →
Cited landmark trials not yet in the register6
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2018ASCEND
Aspirin for primary prevention in diabetes — modest ischaemic benefit, offset by bleeding.
- 2018ASPREE
Aspirin gave no cardiovascular benefit in healthy older adults and increased mortality.
- 2018ARRIVE
Aspirin in moderate-risk primary prevention — no benefit, more gastrointestinal bleeding.
- 1995WOSCOPS
The first primary-prevention statin trial.
- 2008MESA
The cohort behind the coronary artery calcium score and the MESA risk calculator.
- 2013Look AHEAD
Intensive lifestyle intervention in type 2 diabetes — weight loss without a reduction in cardiovascular events.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.